Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Daiichi Sankyo
US Department of Justice
McKinsey
Medtronic
Accenture

Generated: June 24, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,850,229

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,850,229
Title:Compounds and compositions as protein kinase inhibitors
Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
Inventor(s): Huang; Shenlin (San Diego, CA), Jin; Xianming (San Ramon, CA), Liu; Zuosheng (San Diego, CA), Poon; Daniel (Piedmont, CA), Tellew; John (La Jolla, CA), Wan; Yongqin (Irvine, CA), Wang; Xing (San Diego, CA), Xie; Yongping (San Diego, CA)
Assignee: Array BioPharma, Inc. (Boulder, CO)
Application Number:15/179,385
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 9,850,229
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 9,850,229

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-001 Jun 27, 2018 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial INDICATED IN COMBINATION WITH BINIMETINIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION ➤ Try a Free Trial
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-002 Jun 27, 2018 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial INDICATED IN COMBINATION WITH BINIMETINIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION ➤ Try a Free Trial
Array Biopharma Inc MEKTOVI binimetinib TABLET;ORAL 210498-001 Jun 27, 2018 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 9,850,229

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 077975 ➤ Try a Free Trial
Australia 2010286569 ➤ Try a Free Trial
Canada 2771775 ➤ Try a Free Trial
China 102725283 ➤ Try a Free Trial
China 103896921 ➤ Try a Free Trial
Colombia 6612222 ➤ Try a Free Trial
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Queensland Health
AstraZeneca
Accenture
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.